Skip to main content
placeholder image

Phase II study of sequential first-line pazopanib (PAZ) followed by everolimus (EVE) in patients (pts) with advanced or metastatic renal cell carcinoma (RCC) (CATChEz Study).

Journal Article


Abstract


UOW Authors


  •   De Souza, Paul (external author)

Publication Date


  • 2018

Citation


  • de Souza, P. L., Wong, S., Sewak, S., Kotasek, D., Keam, B., Chung, J., . . . Mainwaring, P. N. (2018). Phase II study of sequential first-line pazopanib (PAZ) followed by everolimus (EVE) in patients (pts) with advanced or metastatic renal cell carcinoma (RCC) (CATChEz Study).. Journal of Clinical Oncology, 36(6_suppl), 648. doi:10.1200/jco.2018.36.6_suppl.648

Web Of Science Accession Number


Start Page


  • 648

End Page


  • 648

Volume


  • 36

Issue


  • 6_suppl

Place Of Publication


Abstract


UOW Authors


  •   De Souza, Paul (external author)

Publication Date


  • 2018

Citation


  • de Souza, P. L., Wong, S., Sewak, S., Kotasek, D., Keam, B., Chung, J., . . . Mainwaring, P. N. (2018). Phase II study of sequential first-line pazopanib (PAZ) followed by everolimus (EVE) in patients (pts) with advanced or metastatic renal cell carcinoma (RCC) (CATChEz Study).. Journal of Clinical Oncology, 36(6_suppl), 648. doi:10.1200/jco.2018.36.6_suppl.648

Web Of Science Accession Number


Start Page


  • 648

End Page


  • 648

Volume


  • 36

Issue


  • 6_suppl

Place Of Publication